Experts from the Society for Cardiovascular Angiography and Interventions (SCAI) recommended the use of renal artery stenting to benefit patients who historically were excluded from clinical trials in a document published Aug. 19 in Catheterization and Cardiovascular Intervention.

Participants enrolled in cardiovascular clinical trials may be a poor representation of patients with MI, according to an analysis published Aug. 27 in JAMA. Researchers found enrollees generally to be healthier, younger and have a better prognosis than eligible nonparticipants.

Venous thromboembolism (VTE) risks in patients taking aspirin were significantly reduced over nontreatment in a study published online Aug. 25  in Circulation.

The best way to reduce a patient’s blood pressure may be by getting the patient more involved. Hypertension patients not only effectively self-managed, but saw a greater reduction in mean blood pressure compared to those who did not, according to a study published in the Aug. 27 issue of JAMA.

Joint PCI decision-making may be a best practice, but it appears physicians aren’t encouraging it through their communication styles, according to a paper published online Aug. 25 in JAMA: Internal Medicine.

The FDA approved a cardiac resynchronization therapy-pacemaker (CRT-P) for patients with heart failure or atrioventricular block.

Hospitals that want to add efficiencies to their peripheral artery disease (PAD) programs might take a page from PCI’s playbook. Just as same-day PCI can be feasible and safe for selected patients, same-day discharge after angioplasty may be possible for PAD patients.

The FDA gave the green light to apixaban as a treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE) and to reduce the risk of DVT and PE recurrence.